CTIS2023-507128-22-00招募中1 期
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of NIDO-361 in Patients with Spinal and Bulbar Muscular Atrophy (SBMA) - NIDO-361-002
ido Biosciences Inc.0 个研究点目标入组 54 人开始时间: 2023年10月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •1. Ability to understand the written study informed consent form(s) (ICF(s)) and provide signed written informed consent prior to any study procedures, 10.A participant, who is non-sterilized and sexually active with a female partner of childbearing potential, agrees to use adequate contraception from the signing of the informed consent throughout the duration of the study and 90 days from the last dose. Adequate methods of contraception are described in Section 5.3. In addition, participants must be willing to forgo sperm donation for the duration of the study and 3 months after last dose of study drug., 2. Ambulatory male, 3. Age =18 to =70 years old, 4. Body mass index (BMI) =18 kg/m2 to =32 kg/m2, 5. Documented SBMA diagnosis confirmed by DNA genetic testing, 6. Able to complete six-minute walk test (6MWT), 7. Spinal and Bulbar Muscular Atrophy Functional Rating Scale (SBMAFRS) scores =25 and =45, 8. On initial whole-body magnetic resonance imaging (MRI), patient has evidence of muscle fat replacement such that the total volume of disease affected muscle (i.e., muscle with at least 10% muscle fat infiltration (MFI) and no more than 50% muscle fat fraction (MFF)is at least: - 500 cm3 if only 1 muscle is eligible, or - 250 cm3 if more than one muscle meets the criteria, 9.If using supplements or vitamins, dosing must be stable for at least eight weeks prior to Screening Visit
排除标准
- •1.Use of other investigational drugs within 30 days or 5 half-lives prior to the planned first drug administration, whichever is longer, 10.History of malignancy or has received treatment for malignancy, other than treatment for basal cell or squamous cell carcinoma of the skin, within the previous 5 years, 11.Positive for Hepatis B virus (HBV) or Hepatis C virus (HCV), 12.Known to be positive for human immunodeficiency virus (HIV), 13.Inability to undergo MRI (mild sedation may be allowed), 14.Involved directly or indirectly in the conduct and administration of this study as an Investigator, sub-investigator, study coordinator, or other study staff member, or the patient is a first-degree family member, significant other, or relative residing with one of the above persons involved directly or indirectly in the study, 15.History of hypersensitivity to the excipients of NIDO-361, 2.History of a prior treatment with androgen reducing agents including luteinizing hormone-releasing hormone (LHRH) agonists or antagonists, androgen receptor antagonists, and selective androgen receptor modifiers (SARMs) within the past 3 months or 5 half-lives of the treatment, whichever is longer, 3.History of use of medicines that are known to increase the risk of seizures within 90 days prior to Day 1 and until 90 days after the last study dose, 4.Clinically significant cardiovascular, endocrine, hepatic, renal, pulmonary, gastrointestinal, neurologic, immunologic, malignant, metabolic, psychiatric, or other condition that, in the opinion of the Investigator, precludes the participant’s safe participation in the study or would interfere with the study assessments, 5. Clinically significant abnormality at Screening electrocardiogram (ECG), including but not necessarily limited to a confirmed QT interval corrected for heart rate (QTc) =450 msec for males, 6.Clinically significant laboratory abnormality at Screening Visit, 7.History of substance abuse disorder, (except nicotine) within 6 months prior to the Screening Visit, 8.History of epilepsy or previous seizure within 10 years prior to the Screening Visit, 9.Positive for opioids (unprescribed), cocaine, amphetamines, methadone, barbiturates, methamphetamine, or phencyclidine at the Screening Visit
研究者
相似试验
进行中（未招募）
1 期
A clinical study to determine safety and efficacy of study drug GL-0817 in patients with High-Risk Squamous Cell Carcinoma of the Oral CavityPrevention of Recurrence in HLA-A2+ Patients with High-Risk Squamous Cell Carcinoma of the Oral CavityMedDRA version: 20.0Level: HLTClassification code 10026660Term: Malignant oral cavity neoplasmsSystem Organ Class: 100000004856EUCTR2016-001256-22-HUGliknik Inc228
进行中（未招募）
1 期
AChronic Inducible UrticariaMedDRA version: 23.0Level: LLTClassification code 10012499Term: Dermatographic urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-006447-95-PLCelldex Therapeutics180
进行中（未招募）
1 期
A Phase 2 Clinical Study to Assess the Safety and Efficacy of BMS-986165 in Participants with Active DLE and/or SCLEActive Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)MedDRA version: 21.1Level: PTClassification code 10056509Term: Cutaneous lupus erythematosusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.1Level: PTClassification code 10057903Term: Subacute cutaneous lupus erythematosusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.1Level: LLTClassification code 10013072Term: Discoid lupus erythematosusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2020-000071-21-FRBristol-Myers Squibb International Corporation150
进行中（未招募）
不适用
A study with four oral anti-Hepatitis drugs in patients with Hepatitis C who have already had at least one round of treatment.EUCTR2011-002748-28-DEGilead Sciences Inc.170
进行中（未招募）
不适用
This is a clinical research study involving an experimental drug named GS-6624 for the treatment of metastatic colorectal adenocarcinoma, a sub-type of cancer of the colon and/or rectum. The purpose of this study is to test the effectiveness and safety of GS-6624 at different dose levels when it is given with FOLFIRI. We want to find out what effects, good and/or bad, GS-6624 has on you and your metastatic colorectal adenocarcinoma when it is given with FOLFIRI.Metastatic KRAS Mutant Colorectal AdenocarcinomaMedDRA version: 17.1Level: PTClassification code 10052360Term: Colorectal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003754-61-PLGilead Sciences, Inc.266